Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology

E. Chiappini, C. Petrolini, C. Caffarelli, M. Calvani, F. Cardinale, M. Duse, A. Licari, S. Manti, A. Martelli, D. Minasi, M. Miraglia Del Giudice, G. B. Pajno, C. Pietrasanta, L. Pugni, M. A. Tosca, F. Mosca, G. L. Marseglia

Research output: Contribution to journalReview article

Abstract

Hexavalent vaccines, protecting against six diseases (diphtheria, tetanus, pertussis [DTaP], poliovirus, hepatitis B virus [HBV], and Haemophilus influenzae type b [Hib], are routinely the standard of care in Europe. The use of combined vaccines allows the reduction of number of injections and side effects, the reduction of costs, and the increase in adherence of the family to the vaccination schedule both in terms of the number of doses and timing. The safety profile, efficacy and effectiveness of hexavalent vaccines have been extensively documented in infants and children born at term, and data are accumulating in preterm infants. Hexavalent vaccines are particularly important for preterm infants, who are at increased risk for severe forms of vaccine preventable diseases. However, immunization delay has been commonly reported in this age group. All the three hexavalent vaccines currently marketed in Italy can be used in preterm infants, and recent data confirm that hexavalent vaccines have a similar or lower incidence of adverse events in preterm compared to full-term infants; this is likely due to a weaker immune system response and reduced ability to induce an inflammatory response in preterm infants. Apnoea episodes are the adverse events that can occur in the most severe preterm infants and / or with history of respiratory distress. The risk of apnoea after vaccination seems to be related to a lower gestational age and a lower birth weight, supporting the hypothesis that it represents an unspecific response of the preterm infant to different procedures. High seroprotection rates have been reported in preterm infants vaccinated with hexavalent vaccine. However, a lower gestational age seems to be associated with lower antibody titres against some vaccine antigens (e.g. HBV, Hib, poliovirus serotype 1, and pertussis), regardless of the type of hexavalent vaccine used. Waiting for large effectiveness studies, hexavalent vaccines should be administered in preterm infants according to the same schedule recommended for infants born at term, considering their chronological age and providing an adequate monitoring for cardio-respiratory events in the 48-72 h after vaccination, especially for infants at risk of recurrence of apnoea.

Original languageEnglish
Article number145
JournalItalian Journal of Pediatrics
Volume45
Issue number1
DOIs
Publication statusPublished - Nov 19 2019

    Fingerprint

Keywords

  • Hexavalent vaccines
  • Preterm infants
  • Vaccines

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Chiappini, E., Petrolini, C., Caffarelli, C., Calvani, M., Cardinale, F., Duse, M., Licari, A., Manti, S., Martelli, A., Minasi, D., Miraglia Del Giudice, M., Pajno, G. B., Pietrasanta, C., Pugni, L., Tosca, M. A., Mosca, F., & Marseglia, G. L. (2019). Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology. Italian Journal of Pediatrics, 45(1), [145]. https://doi.org/10.1186/s13052-019-0742-7